Overview

This is a summary of the European public assessment report (EPAR) for Idelvion. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Idelvion.

For practical information about using Idelvion, patients should read the package leaflet or contact their doctor or pharmacist.

Idelvion is a medicine used to prevent and treat bleeding in patients with haemophilia B, an inherited bleeding disorder caused by lack of a clotting protein called factor IX. It can be used in patients of all ages.

Because the number of patients with haemophilia B is low, the disease is considered ‘rare’, and Idelvion was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 4 February 2010.

Idelvion contains the active substance albutrepenonacog alfa.

Idelvion can only be obtained with a prescription, and treatment should be supervised by a doctor with experience in treating haemophilia.

Idelvion is available as powder and solvent that are mixed together to make a solution for injection into a vein. The dose and the frequency of the injections depend on the patient’s bodyweight and whether Idelvion is used to treat or prevent bleeding, as well as the severity of the patient’s factor IX deficiency, the extent and location of the bleeding and the patient’s age and health. For further information on how to use this medicine, see the summary of product characteristics (also part of the EPAR).

Patients with haemophilia B lack factor IX, a protein needed for normal clotting of the blood, and as a result, they bleed readily. The active substance in Idelvion, albutrepenonacog alfa, works in the body in the same way as human factor IX. It replaces the missing factor IX, thereby helping the blood to clot and giving temporary control of bleeding.

In a study in 80 adults and adolescents and another study in 27 children aged less than 12 years, Idelvion was effective at preventing bleeding, with most patients experiencing no bleeding while on preventive treatment. Furthermore, Idelvion was effective in treating bleeding episodes when they did occur; around 93% of the bleeding episodes resolved with one Idelvion injection.

Hypersensitivity (allergic) reactions can occur rarely with Idelvion and include: swelling, burning and stinging at the injection site, chills, flushing, itchy rash, headache, hives, low blood pressure, lethargy, nausea and vomiting, restlessness, a fast heartbeat, tightness of the chest and wheezing. In some cases these reactions can become severe.

Some patients taking factor IX medicines may develop inhibitors (antibodies) against factor IX, causing the medicine to stop working and resulting in a loss of bleeding control. Factor IX medicines can also potentially cause problems due to the formation of blood clots in the blood vessels. For the full list of side effects reported with Idelvion, see the package leaflet.

Idelvion must not be used in patients who are hypersensitive (allergic) to the active substance or other ingredients of the medicine. It must also not be used in patients allergic to hamster proteins.

Studies show that Idelvion is effective at preventing and treating bleeding episodes in patients with haemophilia B, and its safety is comparable to that of other factor IX products. The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Idelvion’s benefits are greater than its risks and recommended that it be approved for use in the EU.

A risk management plan has been developed to ensure that Idelvion is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Idelvion, including the appropriate precautions to be followed by healthcare professionals and patients.

The European Commission granted a marketing authorisation valid throughout the European Union for Idelvion on 11 May 2016.

For more information about treatment with Idelvion, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Idelvion : EPAR - Summary for the public

български (BG) (102.76 KB - PDF)
español (ES) (75.7 KB - PDF)
čeština (CS) (101.67 KB - PDF)
dansk (DA) (76.58 KB - PDF)
Deutsch (DE) (76.71 KB - PDF)
eesti keel (ET) (73.39 KB - PDF)
ελληνικά (EL) (105.13 KB - PDF)
français (FR) (76.38 KB - PDF)
hrvatski (HR) (95.33 KB - PDF)
italiano (IT) (75.09 KB - PDF)
latviešu valoda (LV) (96.17 KB - PDF)
lietuvių kalba (LT) (98.76 KB - PDF)
magyar (HU) (96.47 KB - PDF)
Malti (MT) (100.78 KB - PDF)
Nederlands (NL) (75.27 KB - PDF)
polski (PL) (101.58 KB - PDF)
português (PT) (75.82 KB - PDF)
română (RO) (96.24 KB - PDF)
slovenčina (SK) (99.11 KB - PDF)
slovenščina (SL) (93.11 KB - PDF)
Suomi (FI) (74.66 KB - PDF)
svenska (SV) (74.28 KB - PDF)

Idelvion : EPAR - Risk-mangement-plan summary

Product information

Idelvion : EPAR - Product Information

български (BG) (323.92 KB - PDF)
español (ES) (300.44 KB - PDF)
čeština (CS) (311.25 KB - PDF)
dansk (DA) (296.69 KB - PDF)
Deutsch (DE) (310.56 KB - PDF)
eesti keel (ET) (376.75 KB - PDF)
ελληνικά (EL) (318.11 KB - PDF)
français (FR) (297.55 KB - PDF)
hrvatski (HR) (291.21 KB - PDF)
íslenska (IS) (306.44 KB - PDF)
italiano (IT) (303.11 KB - PDF)
latviešu valoda (LV) (291.06 KB - PDF)
lietuvių kalba (LT) (303.36 KB - PDF)
magyar (HU) (308.96 KB - PDF)
Malti (MT) (351.5 KB - PDF)
Nederlands (NL) (301.99 KB - PDF)
norsk (NO) (297.6 KB - PDF)
polski (PL) (312.2 KB - PDF)
português (PT) (301.08 KB - PDF)
română (RO) (335.84 KB - PDF)
slovenčina (SK) (306.22 KB - PDF)
slovenščina (SL) (295.75 KB - PDF)
Suomi (FI) (286.19 KB - PDF)
svenska (SV) (282.39 KB - PDF)

Latest procedure affecting product information: IB/0068

12/09/2023

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Idelvion : EPAR - All Authorised presentations

български (BG) (60.79 KB - PDF)
español (ES) (72.65 KB - PDF)
čeština (CS) (77.72 KB - PDF)
dansk (DA) (60.31 KB - PDF)
Deutsch (DE) (60.63 KB - PDF)
eesti keel (ET) (69.4 KB - PDF)
ελληνικά (EL) (67.52 KB - PDF)
français (FR) (83.95 KB - PDF)
hrvatski (HR) (66.73 KB - PDF)
íslenska (IS) (58.23 KB - PDF)
italiano (IT) (55.44 KB - PDF)
latviešu valoda (LV) (72.94 KB - PDF)
lietuvių kalba (LT) (75.9 KB - PDF)
magyar (HU) (77.03 KB - PDF)
Malti (MT) (77.35 KB - PDF)
Nederlands (NL) (76.78 KB - PDF)
norsk (NO) (55.54 KB - PDF)
polski (PL) (79.53 KB - PDF)
português (PT) (58.53 KB - PDF)
română (RO) (73.17 KB - PDF)
slovenčina (SK) (75.89 KB - PDF)
slovenščina (SL) (71.17 KB - PDF)
Suomi (FI) (46.54 KB - PDF)
svenska (SV) (59.31 KB - PDF)

Product details

Name of medicine
Idelvion
Active substance
albutrepenonacog alfa
International non-proprietary name (INN) or common name
albutrepenonacog alfa
Therapeutic area (MeSH)
Hemophilia B
Anatomical therapeutic chemical (ATC) code
B02BD04

Pharmacotherapeutic group

Antihemorrhagics

Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

Authorisation details

EMA product number
EMEA/H/C/003955

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Marketing authorisation holder
CSL Behring GmbH

Emil-von-Behring-Straße 76
35041 Marburg
Germany

Opinion adopted
25/02/2016
Marketing authorisation issued
11/05/2016
Revision
12

Assessment history

Idelvion : EPAR - Procedural steps taken and scientific information after authorisation

Idelvion : EPAR - Assessment report - Variation

Idelvion : EPAR - Public assessment report

CHMP summary of positive opinion for Idelvion

Topics

This page was last updated on

How useful do you find this page?